ovarian cancer

Showing NaN - NaN of 220

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)

Not yet recruiting
  • Solid Tumor, Adult
  • +19 more
  • A2B694
  • xT CDx with HLA-LOH Assay
  • Duarte, California
  • +9 more
Sep 22, 2023

Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)

Not yet recruiting
  • Ovarian Cancer
  • Malignant Neoplasm of Uterus
  • New York, New York
    Icahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023

Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified

Recruiting
  • Endometrial Cancer
  • +8 more
  • Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
  • Orlando, Florida
  • +21 more
Feb 2, 2023

Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Worldwide (biological, drug, other)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Pembrolizumab
  • +4 more
  • Phoenix, Arizona
  • +178 more
Jan 25, 2023

Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer Trial in New York, Fairfax, Spokane (XMT-1660)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Orange, California
  • +6 more
Jan 23, 2023

Ovarian Cancer, NSCLC, ESCC Trial in United States (ASP0739, Pembrolizumab)

Active, not recruiting
  • Ovarian Cancer
  • +3 more
  • Duarte, California
  • +6 more
Jan 21, 2023

Ovarian Cancer Trial in Worldwide (Ipatasertib, Cobimetinib, Trastuzumab Emtansine)

Recruiting
  • Ovarian Cancer
  • Tucson, Arizona
  • +60 more
Jan 20, 2023

Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

Recruiting
  • Minimal Residual Disease
  • +11 more
  • ELI-002 2P
  • Duarte, California
  • +10 more
Jan 18, 2023

Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)

Recruiting
  • Advanced Malignancies
  • +4 more
  • Fayetteville, Arkansas
  • +61 more
Jan 10, 2023

OVARIAN CANCER Trial in Worldwide (Cobimetinib, Niraparib, Atezolizumab)

Recruiting
  • OVARIAN CANCER
  • Tucson, Arizona
  • +28 more
Jan 10, 2023

NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +32 more
Jan 4, 2023

Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))

Completed
  • Ovarian Cancer
  • +7 more
  • Enapotamab vedotin (HuMax-AXL-ADC)
  • Phoenix, Arizona
  • +40 more
Dec 12, 2022

Ovarian Cancer Trial in Worldwide (VS-6766, VS-6766 and Defactinib)

Recruiting
  • Low Grade Ovarian Serous Adenocarcinoma
  • Ovarian Cancer
  • avutometinib (VS-6766)
  • avutometinib (VS-6766) and Defactinib
  • Scottsdale, Arizona
  • +46 more
Dec 29, 2022

Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)

Active, not recruiting
  • Advanced Solid Malignancy
  • +13 more
  • Los Angeles, California
  • +33 more
Dec 22, 2022

NSCLC, Ovarian Cancer, Melanoma Trial in Worldwide (LXH254, PDR001)

Terminated
  • NSCLC
  • +3 more
  • Boston, Massachusetts
  • +17 more
Dec 20, 2022

Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)

Terminated
  • Platinum Sensitive Ovarian Cancer
  • Ovarian Cancer
  • FRĪ± peptide plus Adjuvant (GM-CSF)
  • Adjuvant (GM-CSF) Alone
  • Birmingham, Alabama
  • +17 more
Nov 21, 2022

Ovarian Cancer Trial in Worldwide (Alpelisib, Olaparib, Paclitaxel)

Recruiting
  • Ovarian Cancer
  • Phoenix, Arizona
  • +116 more
Nov 25, 2022

Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or

Active, not recruiting
  • Melanoma
  • +8 more
  • Los Angeles, California
  • +9 more
Nov 15, 2022

Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer Trial in Duarte, Louisville, New York (PF-07263689, Sasanlimab)

Active, not recruiting
  • Renal Cell Cancer
  • +9 more
  • PF-07263689
  • Sasanlimab
  • Duarte, California
  • +5 more
Nov 8, 2022

Melanoma, Ovarian Cancer, Sarcoma Trial in Italy, Portugal, United States (IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in

Active, not recruiting
  • Melanoma
  • +6 more
  • IGIMRT using a single dose of 24 Gy
  • IGIMRT 27 Gy in 3 fractions
  • San Francisco, California
  • +3 more
Nov 1, 2022

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Ovarian Cancer Trial in Worldwide (cisplatin)

Recruiting
  • Ovarian Cancer
  • New York, New York
  • +20 more
Oct 17, 2022

Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)

Terminated
  • Ovarian Cancer
  • Monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer Trial in New York (NY-ESO-1 peptide vaccine)

Completed
  • Fallopian Tube Cancer
  • +2 more
  • NY-ESO-1 peptide vaccine
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022